新型靶向治疗在小细胞肺癌中的作用。

The role of new targeted therapies in small-cell lung cancer.

作者信息

Rossi A, Maione P, Colantuoni G, Guerriero C, Gridelli C

机构信息

Unità Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, 83100-Avellino, Italy.

出版信息

Crit Rev Oncol Hematol. 2004 Jul;51(1):45-53. doi: 10.1016/j.critrevonc.2004.02.003.

DOI:10.1016/j.critrevonc.2004.02.003

PMID:15207253

Abstract

Lung cancer is the leading world-wide cause of cancer death. Small-cell lung cancer (SCLC) accounts for 20-25% of lung carcinomas. Chemotherapy is the cornerstone of treatment of SCLC. In limited disease, median survival is about 12-16 months with 4-5% of long-term survivors, in extensive disease median survival is 7-11 months. Improving the survival rate of patients with SCLC requires a better understanding of tumour biology and the subsequent development of novel therapeutic strategies. Several targeted agents have been introduced into clinical trials in SCLC and some phase III studies have already produced definitive results. Currently, the minority of these new agents offers a promise of improved outcomes, and negative results are more commonly reported than positive ones. To date, no targeted therapy has been approved for use in the treatment of patients with SCLC. This review will focus on the main novel biologic agents investigated in the treatment of SCLC.

摘要

肺癌是全球癌症死亡的主要原因。小细胞肺癌（SCLC）占肺癌的20%-25%。化疗是小细胞肺癌治疗的基石。在局限性疾病中，中位生存期约为12-16个月，长期生存率为4%-5%；在广泛性疾病中，中位生存期为7-11个月。提高小细胞肺癌患者的生存率需要更好地了解肿瘤生物学，并随后开发新的治疗策略。几种靶向药物已被引入小细胞肺癌的临床试验，一些III期研究已经产生了明确的结果。目前，这些新药物中少数有望改善治疗结果，而且报告的阴性结果比阳性结果更为常见。迄今为止，尚无靶向治疗被批准用于治疗小细胞肺癌患者。本综述将聚焦于在小细胞肺癌治疗中研究的主要新型生物制剂。